A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer by Nabil Mubarak et al.
Mubarak et al. BMC Cancer 2012, 12:423
http://www.biomedcentral.com/1471-2407/12/423RESEARCH ARTICLE Open AccessA randomized, phase 2 study comparing
pemetrexed plus best supportive care versus
best supportive care as maintenance therapy
after first-line treatment with pemetrexed
and cisplatin for advanced, non-squamous,
non-small cell lung cancer
Nabil Mubarak1*, Rabab Gaafar2, Samir Shehata3, Tarek Hashem4, Dani Abigeres5, Hamdy A Azim6,
Gamal El-Husseiny7, Hamed Al-Husaini8 and Zhixin Liu9Abstract
Background: Maintenance therapy for non-small cell lung cancer (NSCLC) aims to extend disease control after
first-line chemotherapy with active and well-tolerated agents. The utility of continuation maintenance therapy
requires further research.
Methods: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with
pemetrexed (500 mg/m2 every 21 days) and best supportive care (BSC) versus BSC alone in patients with advanced,
non-squamous NSCLC who had not progressed after 4 cycles of induction chemotherapy with pemetrexed
(500 mg/m2) and cisplatin (75 mg/m2). The primary endpoint was progression-free survival (PFS) from
randomization, was analyzed using a Cox model, stratified for the tumor response at the end of induction therapy,
at a one-sided alpha of 0.2. Secondary endpoints: response and disease control rates, overall survival (OS), one year
survival rates, and treatment-emergent adverse events (TEAEs).
Results: A total of 106 patients commenced induction therapy, of whom 55 patients were randomized to
maintenance pemetrexed/BSC (n = 28) or BSC (n = 27). Although the median PFS time for maintenance phase for
both arms was 3.2 months, the one-sided p-value for the PFS HR comparison was less than the prespecified limit of
0.2 (HR = 0.76, two-sided 95% confidence interval [CI]: 0.42 to 1.37; one-sided p-value = 0.1815), indicating that PFS
was sufficiently long in the pemetrexed/BSC arm to warrant further investigation. Similar PFS results were observed
for the overall study period (induction plus maintenance) and when the PFS analysis was adjusted for sex, baseline
disease stage, and the ECOG PS prior to randomization. The median OS for the maintenance phase was
12.2 months (95%CI: 5.6 to 20.6) for the pemetrexed/BSC arm and 11.8 months (95% CI: 6.3 to 25.6) for BSC arm.
The one-year survival probabilities were similar for both arms for the maintenance phase and the overall study
period. Both the induction and continuation maintenance therapies were generally well-tolerated, and similar
proportion of patients in each arm experienced at least 1 grade 3/4 TEAE (pemetrexed/BSC, 17.9%; BSC, 18.5%).
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Conclusions: Continuation pemetrexed maintenance therapy resulted in promising PFS with an acceptable safety
profile in a Middle Eastern population with advanced non-squamous NSCLC and is worthy of further investigation.
Trial registration: NCT00606021
Keywords: Non-squamous, Non-small cell lung cancer, Pemetrexed, Cisplatin, Induction, MaintenanceBackground
In patients with advanced non-small cell lung cancer
(NSCLC), there is generally a brief period of disease
control after response to first-line chemotherapy. Conse-
quently, there is a great need to find more effective and
tolerable treatments and strategies to delay progression
and improve survival in advanced stage NSCLC. A key
consideration for maintenance therapy is to utilize a
well-tolerated agent with a relatively low risk of serious,
cumulative toxicities. In advanced NSCLC, maintenance
therapy is typically initiated after 4-6 cycles of induction
chemotherapy with an active doublet and is continued
until disease progresses or unacceptable toxicity is reached.
Maintenance therapy options include: continuing the
induction therapy regimen; continuing the non-platinum
or molecularly targeted component of the first-line regi-
men (‘continuation maintenance’); or introducing a new
cytotoxic or molecularly targeted agent after induction
therapy (‘switch’ maintenance) [1,2].
Pemetrexed is a multitargeted, antifolate cytotoxic
agent that disrupts folate-dependent metabolic processes
essential for cell replication through the inhibition of the
enzymes thymidylate synthase (TS), dihydrofolate reduc-
tase (DHFR), and glycinamide ribonucleotide formyl-
transferase (GARFT). Pemetrexed received approval of
the U.S. Food and Drug Administration (FDA) as initial
therapy in combination with cisplatin, as monotherapy
after prior chemotherapy, and as maintenance mono-
therapy in patients with locally advanced or metastatic
non-squamous NSCLC whose disease has not progressed
after four cycles of platinum-based first-line chemother-
apy [3]. Pemetrexed is generally well tolerated; however,
its multiple enzyme inhibitions also account for the
potentially adverse effects of pemetrexed, including mye-
losuppression (mainly transient neutropenia), oral muco-
sitis, diarrhea, and rash/desquamation. It has been found
that the hematological and non-hematological toxicities
of pemetrexed can be reduced through routine vitamin
supplementation (folic acid and vitamin B12), without
loss of efficacy [4]. The efficacy and safety of switch
maintenance therapy with pemetrexed has been exam-
ined in a previous randomized, double-blind, multi-
national, phase 3 study [5]. In that study, patients
with advanced NSCLC with a good baseline performance
status (0 or 1) who did not have disease progression afterfour cycles of permitted platinum-based chemotherapy
(not including pemetrexed) were randomly assigned in a
2:1 ratio to receive switch maintenance therapy with
pemetrexed (500 mg/m2, Day 1) plus best supportive
care (BSC) or placebo plus BSC in 21-day cycles until
disease progression. The primary endpoint of PFS and
the secondary endpoint of OS were analyzed by intention
to treat. The PFS was statistically significantly longer in
the pemetrexed/BSC arm than in the placebo/BSC arm
(median PFS: 4.3 vs 2.6 months, respectively; hazard
ratio [HR] = 0.50, 95% CI: 0.42-0.61, p < 0.0001). Overall
survival (OS) was also significantly improved for the
pemetrexed/BSC arm compared to the placebo/BSC arm
(median OS: 13.4 vs 10.6 months, respectively; HR= 0.79,
95% CI: 0.65-0.95; p = 0.012) [5]. To provide a more
comprehensive assessment of the therapeutic benefit of
pemetrexed maintenance therapy, quality of life was also
examined. In a recently published trial, the results of
the quality assessment of these patients were disclosed.
Patients were analyzed by the Lung Cancer Symptom
Scale. Patients treated with pemetrexed maintenance
therapy (500 mg/m2 every 21 days; n = 441) showed
a longer time to worsening of pain (HR=0.76) and
hemoptysis (HR= 0.58) compared with patients given
placebo (n = 222), without high rates of toxic effects [6].
Consistent with data from other studies of pemetrexed
as first- or second-line treatment for advanced NSCLC,
prespecified subgroup analyses showed that there were
significant treatment-by-histology interactions for both
PFS and OS, such that the improvements in PFS and OS
were observed mainly in patients with non-squamous
histology [5,7].
Due to the favorable results observed for switch
maintenance therapy with pemetrexed, we conducted a
randomized, phase 2 trial to examine the feasibility of
continuation maintenance therapy with pemetrexed in
patients with advanced, non-squamous NSCLC. After
completing four cycles of first-line induction therapy
with pemetrexed and cisplatin, patients without disease
progression were randomized to receive maintenance
therapy with either pemetrexed and BSC or BSC alone.
The primary outcome measure was PFS from randomiza-
tion. Secondary endpoints included: the overall response
rate, the disease control rate, OS, one-year survival rates,
and treatment-emergent adverse events.
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Study design
This was a multicenter, randomized, open-label, parallel-
arm, phase 2 trial conducted at 8 investigative sites in 3
countries: Egypt, Lebanon, and Saudi Arabia. The first
patient was entered into the study in January 2008 and
the last patient completed the study in December 2010.
The study was conducted in accordance with the Declar-
ation of Helsinki and Good Clinical Practice guidelines.
The study was approved by the ethics review board at
each investigative site and all patients provided their
written informed consent. The trial was registered at
www.clinicaltrials.gov (NCT00606021).
Patient eligibility
Eligible patients were aged ≥18 years, had an estimated
life expectancy of ≥12 weeks, and an Eastern Coopera-
tive Oncology Group performance status (ECOG PS) of
0 or 1. Other eligibility criteria included: a histologic
or cytologic diagnosis of Stage IIIB (with pleural effu-
sion and/or positive supraclavicular nodes) or Stage IV
NSCLC (using the sixth edition TNM staging system
available at the time the study was conducted) with non-
squamous histology that was not amenable to curative
therapy; no prior systemic anticancer therapy for lung
cancer; a calculated creatinine clearance (CrCl) ≥45 mL/
min based on the standard Cockcroft and Gault formula
and a serum creatinine <1.5 x ULN; an adequate bone
marrow reserve and liver function; and at least one uni-
dimensionally measurable lesion according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST;
version 1.0)[8]. Prior surgery and radiotherapy (limited
to <25% of the bone marrow) were allowed if patients
had recovered at least 4 weeks before the initiation of
induction therapy.
Exclusion criteria included: any serious concomitant
systemic disorder; brain metastasis; clinically significant
third-space fluid collections; significant weight loss (>10%)
during the 6 weeks before study entry; pregnancy or
breast-feeding; inability to interrupt aspirin or other non-
steroidal anti-inflammatory agents for a 5-day period (or
8-day period for long-acting agents such as piroxicam);
inability or unwillingness to take folic acid, dexamethasone
(or equivalent) or vitamin B12 supplementation.
Study treatment
After completing the screening assessments, eligible
patients commenced first-line, induction chemotherapy
with pemetrexed and cisplatin. Pemetrexed (500 mg/m2)
and cisplatin (75 mg/m2) were given intravenously on
Day 1 of each 21-day cycle up to a maximum of 4 cycles
or until disease progression, unacceptable toxicity, or
another permitted reason for discontinuation. Following
induction therapy, patients who still remained in thestudy without disease progression were randomized in a
1:1 ratio to receive continuation maintenance therapy
with pemetrexed (500 mg/m2 every 21 days) and BSC or
BSC alone. Randomization was stratified by the best
overall response to the induction therapy (complete
or partial response [CR or PR] vs stable disease [SD] or
unknown [i.e. although progression had not been docu-
mented, 1 or more target or nontarget sites had not
been assessed]). Maintenance therapy commenced on
Day 1 of the fifth cycle and continued until disease pro-
gression, unacceptable toxicity, or another permitted
reason for discontinuation. The end of the study was set
at 12 months after maintenance phase randomization or
30 days after the end of the maintenance treatment.
Investigators were responsible for providing appropri-
ate BSC. Permitted pemetrexed dose modifications and
delays due to certain toxicities were defined in the
protocol. During the induction and maintenance phases,
all pemetrexed-treated patients were required to take
prophylactic folic acid and vitamin B12 supplementation
(as described in the pemetrexed prescribing information
[9]) and dexamethasone (4 mg orally twice a day or
equivalent the day before, the day of, and the day after
each pemetrexed dose). Higher or additional dexame-
thasone doses were permitted for reasons other than
routine rash prophylaxis (e.g. antiemetic prophylaxis).
Full supportive care therapies were permitted concomi-
tantly during the study, but no other anticancer therap-
ies were permitted.
Study assessments
Tumor assessments were performed by investigators at
each investigative site, per RECIST (version 1.0) require-
ments [8], at baseline (no more than 4 weeks before the
initiation of induction therapy) and every 6 weeks
(±1 week) during study therapy (before the start of every
other treatment cycle). Confirmation of response was
required within ≥28 days and ≤42 days after the first
evidence of response. After study therapy discontinu-
ation, responding or stable patients were required to
have follow-up efficacy assessments approximately every
6 weeks (±1 week) until documented disease progres-
sion, death, or study closure, whichever occurred first.
Patients with documented disease progression were
monitored for survival approximately every 3 months
until death or study closure, whichever occurred first.
Toxicity was assessed at baseline, before the start of
each cycle (during induction phase and maintenance
phase in both arms), and approximately 30 days after the
study therapy discontinuation. Per study protocol ‘treat-
ment emergent adverse events (TEAEs)’ were defined as
any untoward medical occurrence that either occurs or
worsens at any time after treatment baseline and which
does not necessarily have to have a causal relationship
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ing to the Common Terminology Criteria for Adverse
Events (CTCAE), version 3.0. After the 30-day post-
discontinuation safety follow-up visit, only serious
adverse events (SAEs) considered to be related to study
drug or protocol procedures had to be reported and
followed-up at least every 30 days until the event had
resolved, stabilized, or the patient commenced a new
systemic anticancer therapy.
Statistical analysis
The primary objective of the study was to compare PFS
for the maintenance therapy phase for pemetrexed/BSC
vs BSC alone. The study was powered to detect a PFS
HR of 0.56, which was considered to be the effect size
that pemetrexed must have to warrant its further devel-
opment as continuation maintenance therapy, based on
the results of a previous study [10].
The study initially required a total of 44 randomized
patients to have 80% power to detect a true treatment
effect of 0.56 at a one-sided alpha of 0.2, in which case
pemetrexed continuation maintenance therapy would be
considered to warrant further investigation. The planned
randomization ratio for the study was 2:1 to enable the
collection of more data about potential adverse events
(AEs), while maintaining sufficient power to detect a
between-treatment difference in PFS and reducing the
exposure of patients to the potentially inferior BSC main-
tenance ‘therapy’. However, due to an undetected error in
the randomization parameter form, randomization was
actually implemented in a 1:1 ratio, which resulted in a
slight increase in power from 80% to 83%.
Efficacy analyses, other than response-related anal-
yses, were conducted using the qualified intent-to-treat
(Q-ITT) analysis population, which consisted of all ran-
domized patients. Response rates and disease control
rates were analyzed using the tumor analyzable (TA)
population, which included all patients who received at
least one dose of therapy and had measurable or evalu-
able lesions at baseline. For the Q-ITT and TA popula-
tions, patients were analyzed according to the therapy to
which they were randomly assigned. Safety analyses were
conducted with the safety analysis population, which
included all patients who received at least one dose of
study therapy. For the safety analyses for the mainten-
ance phase and the overall study therapy period (induc-
tion and maintenance phases), patients were analyzed
according to the therapy they received in the first cycle
of the maintenance phase.
PFS was measured from the date of randomization to
the date of progression or death. For patients without
documented disease progression who were not known to
have died by the time of analysis, PFS was censored at
the date of the last visit with adequate assessment. Forpatients who received subsequent anticancer therapy
after study therapy discontinuation before disease pro-
gression or death, PFS was censored at the date of last
visit with adequate assessment before the initiation of
the post-discontinuation anticancer therapy.
Cox proportional hazards model, stratified for response
at the end of the induction therapy (CR and PR vs SD),
was used to estimate the PFS HR. In addition, for each
treatment arm, the Kaplan-Meier estimates of the
median PFS and associated 95% CI were calculated. The
unadjusted between-arm comparisons of PFS were con-
ducted using a log rank test and a Wilcoxon test (to ac-
count for early events). The p-value associated with the
Wald Chi-Square test was used for testing whether the
HR was equal to unity at a one-sided alpha of 0.2. In
addition, PFS was calculated for the overall study period
(induction plus maintenance therapy) measured from the
first dose of induction therapy to the date of progression
or death. The potential confounding effect of differences
in certain baseline characteristics (sex, ECOG PS score
before randomization, stage of disease at entry) was also
investigated by including these prespecified characteris-
tics in the primary model.
OS for the maintenance phase was calculated from
randomization to death from any cause. OS for the over-
all study period was calculated from the first dose of
induction therapy to death from any cause. Survival time
was censored at the date of last contact for patients who
were still alive or lost to follow-up. OS was assessed
using the Kaplan-Meier method. Between-arm compari-
sons were made using the log-rank test at a two-sided
significance level of 0.05. The overall response and dis-
ease control rates were calculated for the maintenance
phase and the overall study period, and between-arm
comparisons were performed using the Chi-square test
at a two-sided significance level of 0.05. All analyses
were conducted using SASW software version 9.1.3 (SAS
Institute Inc., Cary, NC).
Results
Patient disposition
Patient disposition is summarized in Figure 1. A total of
108 patients were screened for the study, of whom 1 did
not meet the eligibility criteria and 1 was lost to follow-
up. Therefore, 106 patients were enrolled and received
at least 1 dose of induction therapy. Following the
induction phase, a total of 80 (75.4%) patients had no
disease progression documented, although 55 patients of
them were considered protocol-qualified and were ran-
domized to maintenance treatment with pemetrexed/
BSC (n = 28) or BSC alone (n = 27). All of the patients in
the pemetrexed/BSC arm received at least 1 dose of
maintenance therapy. The most common reason for pre-
mature study discontinuation in both arms was death
Discontinued, n=17 (30.9%)
Reasons for discontinuation:
Death, n=15 ( 55.6%)
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Figure 1 Patient disposition. aCR/PR/SD/UNK=Complete Response (n = 1, 0.9%)/Partial Response (n = 26, 24.5%)/Stable Disease (n = 49, 46.2%),
per RECIST/UNK= unknown (i.e. progression had not been documented, and 1 or more target or nontarget sites had not been assessed [n = 4,
3.8%]) bUnknown= insufficient data Abbreviations: AE = adverse event, BSC = best supportive care, Pem=pemetrexed, PD=progressive disease.
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dominantly due to non-squamous NSCLC. Five (17.9%)
patients in the pemetrexed/BSC arm and 10 (37.0%)
patients in the BSC arm were alive and progression-free
at the end of the study. The main reasons for treatment
discontinuation in the pemetrexed/BSC and BSC arms,
respectively were: progressive disease (64.3% vs 77.8%),
patient decision (17.9% vs 7.4%), and death (14.3% vs
7.4%).Baseline patient characteristics
Table 1 presents some key baseline characteristics for
the randomized patients, before the start of induction
therapy, and the patients’ best tumor response during
the induction therapy phase. Baseline characteristics
were generally similar between the two treatment arms
except that there were slightly higher proportions of
patients who were never smokers or had stage IV disease
in the pemetrexed/BSC arm (pemetrexed/BSC arm,
42.9% and 67.9% vs BSC arm, 37.0% and 63.0%, respect-
ively), and there was a higher proportion of females in
the BSC arm (pemetrexed/BSC arm, 37.0% vs BSC arm,
28.6%). The best overall tumor responses to induction
therapy were generally similar between the arms in
terms of the numbers of responding and stable patients.
The numbers of patients with ECOG PS scores of 0, 1
or 2 at the start of the maintenance phase were generallysimilar between the two maintenance arms (2 patients in
each arm had an ECOG PS of 2; other data not reported
here).Study treatment and additional therapy
Of the 106 patients that initiated induction therapy, 79
(74.5%) patients completed 3 cycles of induction therapy
and 67 (63.2%) patients completed 4 cycles of induction
therapy. During induction therapy, there were very few
dose reductions or delays, and the median dose inten-
sities (defined as the actual dose/planned dose) were
94.0% for pemetrexed and 94.6% for cisplatin. During
the induction phase, all 106 patients were compliant
with the required vitamin B12 supplementation, and
compliance with the required folic acid supplementation
ranged from 89.3-100.0%.
Of the 28 patients in the pemetrexed/BSC mainten-
ance arm, 18 (64.3%) received ≥4 cycles, 7 (25.0%)
received ≥6 cycles, 4 (14.3%) received ≥12 cycles, 3
(10.7%) received 14 cycles, and 1 (3.6%) received
15 cycles. During the maintenance phase, the median
number of cycles of pemetrexed given was 4.0 and the
median dose intensity of pemetrexed was 95.3% (range:
75%-102%). There were no pemetrexed dose reductions
required during the maintenance phase, but 3 (10.7%)
patients required a pemetrexed dose delay for 1 cycle
and 1 (3.6%) patient had 2 delayed cycles. During the
Table 1 Demographic and clinical baseline characteristics






Median age (range), years 61 (22-75) 59 (48-83)
Males, n (%) 20 (71.4) 17 (63.0)
Race, n (%)
Caucasian 26 (92.9) 26 (96.3)
African 2 (7.1) 1 (3.7)
ECOG PS, n (%)
0 8 (28.6) 6 (22.2)
1 20 (71.4) 21 (77.8)
Prior therapy, n (%)
Radiotherapy 2 (7.1) 1 (3.7)
Curative surgery 0 (0.0) 2 (7.4)
Disease stageb, n (%)
IIIB 9 (32.1) 10 (37.0)
IV 19 (67.9) 17 (63.0)
Histologic subtype, n (%)
Adenocarcinoma 19 (67.9) 21 (77.8)
Large cell 8 (28.6) 5 (18.5)
Mixed cell 1 (3.6) 1 (3.7)
Smoking status, n (%)
Current smoker 8 (28.6) 6 (22.2)
Former smoker 8 (28.6) 11 (40.7)
Never smoker 12 (42.9) 10 (37.0)
Best tumor response, n (%)c
Complete response (CR) 0 (0.0) 1 (3.7)
Partial response (PR) 10 (35.7) 11 (40.7)
Stable disease (SD) 17 (60.7) 13 (48.1
Unknown 1 (3.6) 2 (7.4)
Abbreviations: BSC = best supportive care; ECOG PS = Eastern Cooperative
Oncology Group Performance Status.
Note: The sum of percentages for some characteristics do not add up to
100% due to rounding.
aMaintenance phase was defined as visit 5 to the visit prior to the
post-treatment phase (i.e. the data of progression or the start of a new
anti-cancer therapy treatment).
bBased on TNM Classification, 6th edition.
cThe best overall tumor response during the induction therapy phase. This was
used as the stratification factor for randomization to one of the maintenance
phase arms.
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B12 supplementation and an average of 78.7% for folic
acid supplementation. After the discontinuation of study
therapy, a similar proportion of patients in each arm
received at least one type of additional anticancer ther-
apy (pemetrexed/BSC, 46.4%; BSC, 44.4%). The add-
itional therapies were: chemotherapy (39.3% vs 37.0%)
and/or radiotherapy (14.3% vs 14.8%).Progression-free survival and overall survival
The median PFS time for the maintenance phase for
both treatment arms was 3.2 months (pemetrexed/BSC
arm, 95% CI: 2.9 to 6.1; BSC arm, 95% CI: 2.2 to 4.3).
The PFS HR stratified by the best tumor response for
induction therapy was 0.76 (two-sided 95% CI: 0.42 to
1.37; one-sided p-value = 0.1815). When the analysis
model was also adjusted for the 3 prespecified patient
characteristics, PFS remained longer for the pemetrexed/
BSC arm than the BSC arm (maintenance phase: HR=
0.65, 95% CI: 0.35 to 1.20, one-sided p-value = 0.0846;
overall study period: HR= 0.60, 95% CI: 0.33 to 1.09,
one-sided p-value = 0.0461). The median OS time in the
pemetrexed/BSC arm was 12.2 months (95% CI: 5.6 to
20.6) and 11.8 months (95% CI: 6.3 to 25.6) in the BSC
arm (HR: 1.13, two-sided 95% CI: 0.56 to 2.28). Sum-
marized PFS and OS data are shown in Table 2. The
one-year survival probabilities were similar for the two
treatment arms for the maintenance phase (pemetrexed/
BSC, 54.4%; BSC, 49.5%) and the overall study period
(pemetrexed/BSC, 58.6%; BSC, 57.8%). The unadjusted
Kaplan-Meier curves for PFS and OS for each arm are
shown in Figures 2 and 3, respectively.
Tumor response
Of the 106 patients who commenced induction therapy,
27 patients had a best overall response of CR (n = 1,
0.9%) or PR (n = 26, 24.5%), 49 (46.2%) patients had a
best response of SD, and 4 (3.8%) patients were defined
per protocol as unknown. Therefore, the disease control
rate for the induction phase was 71.7% (76/106).
For the maintenance phase, there were no cases of a
best response of CR or PR, thus the overall response rate
was 0.0% for both arms. Sixteen (57.1%) patients in the
pemetrexed/BSC arm and 12 (44.4%) patients in the
BSC arm had a best response of SD.The disease control
rate for the maintenance phase was not significantly dif-
ferent between the pemetrexed/BSC arm and the BSC
arm (57.1% vs 44.4%, p = 0.3463). Nine (32.1%) patients
in the pemetrexed/BSC arm and 10 (37.0%) patients in
the BSC arm showed progressive disease. For the overall
study period, the disease control rate was similar for
both treatment arms (pemetrexed/BSC, 96.4%; BSC,
96.3%; p = 0.9791).
Safety
During the induction phase, 73 (68.9%) patients experi-
enced at least 1 treatment-emergent adverse event
(TEAE) and 65 (61.3%) patients experienced at least 1
drug-related TEAE. Approximately one-third (31.1%) of
the patients experienced at least 1 grade 3/4 TEAE and
12.3% of the patients experienced at least 1 SAE. Twelve
(11.3%) patients died during induction therapy. The
most common TEAEs (≥10%) during the induction
Table 2 Efficacy measures for patients with non-squamous NSCLC by arm (Pemetrexed+BSC vs BSC)
Parameter Median PFS or OS time (95% CI)a, months HR 95% CIa 1-sided
p-valuePemetrexed/BSC (n= 28) BSC (n = 27)
Maintenance Phased
PFS 3.2 (2.9 to 6.1) 3.2 (2.2 to 4.3) 0.76b 0.42 to 1.37b 0.1815b
0.65c 0.35 to 1.20c 0.08465c
OS 12.2 (5.6 to 20.6) 11.8 (6.3 to 25.6) 1.13b 0.56 to 2.28b 0.36195b
0.95c 0.46 to 1.97c 0.4497c
Overall Study Period (induction +maintenance)e
PFS 6.2 (6.0 to 8.3) 6.0 (4.6 to 6.9) 0.71b 0.40 to 1.26b 0.12325b
0.60c 0.33 to 1.09c 0.0461c
OS 15.4 (8.4 to 23.7) 16.4 (9.1 to 28.5) 1.18b 0.59 to 2.38b 0.3188b
1.01c 0.49 to 2.08c 0.48985c
Abbreviations: BSC=best supportive care; CI= confidence interval; ECOG PS= Eastern Cooperative Oncology Group performance status; HR=hazard ratio;
OS=overall survival; PFS=progression-free survival.
aTwo-sided 95% confidence interval.
bStratified for the best tumor response during the induction therapy.
cStratified for the best tumor response during the induction therapy and adjusted for sex, baseline disease stage (before induction therapy), and the ECOG PS
score before the initiation of maintenance therapy.
dMaintenance phase was defined as visit 5 to the visit prior to the post-treatment phase (i.e. the data of progression or the start of a new anti-cancer therapy
treatment).
eExploratory data analysis.
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fatigue (23.6%), nausea (14.2%), anemia (12.3%), and
neutropenia (10.4%). The observed toxicities were con-
sistent with the known safety profile of the induction
therapy regimen.
During the maintenance phase, 12 (42.9%) patients in
the pemetrexed/BSC arm and 9 (33.3%) patients in the
BSC arm experienced at least 1 TEAE. Five patients inTime 
















Figure 2 Unadjusted, unstratified PFS for the maintenance phase (fro
Pemetrexed + BSC: PFS median time= 3.2 months (95% CI = 2.9-6.1) BSC: PF
p-value = 0.1815.each arm experienced at least 1 grade 3/4 TEAE (peme-
trexed/BSC, 17.9%; BSC, 18.5%) and 1 patient in each
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http://www.biomedcentral.com/1471-2407/12/423n= 1, 3.7%). None of the SAEs were drug-related. The
most common (≥5% in at least 1 arm) TEAEs during the
maintenance phase are summarized in Table 3. The pro-
portions of patients that experienced TEAEs during the
maintenance phase were relatively low, and the observed
toxicities for the pemetrexed/BSC arm were mostly mild
to moderate (grade 1 or 2) and not unexpected for
pemetrexed monotherapy. The occurrence of grade 3/4
TEAEs was relatively low in both arms and there were
no significant between-arm differences in the proportion
of patients experiencing any grade 3/4 TEAE. Three
(10.7%) patients required red blood cell transfusions and
1 (3.6%) patient was hospitalized due to NSCLC. FourTable 3 The most common treatment-emergent adverse
events during the maintenance phase (≥5.0%)
TEAE, n (%) Pemetrexed/BSC (n= 28) BSC (n= 27)
All Grades Grade 3/4 All Grades Grade 3/4
Dyspnea 2 (7.1) 0 (0.0) 4 (14.8) 1 (3.7)
Anemia 3 (10.7) 2 (7.1)a 1 (3.7) 1 (3.7)b
Chest/thorax pain 3 (10.7) 0 (0.0) 3 (11.1) 0 (0.0)
Neutropenia 2 (7.1) 2 (7.1)b 0 (0.0) 0 (0.0)
Abnormal ALT 2 (7.1) 0 (0.0) 1 (3.7) 1 (3.7)
Fatigue 1 (3.6) 0 (0.0) 2 (7.4) 1 (3.7)
Nausea 2 (7.1) 0 (0.0) 0 (0.0) 0 (0.0)
Vomiting 2 (7.1) 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviations: ALT= alanine aminotransferase; BSC=best supportive care;
TEAE= treatment-emergent adverse event.
a1 (3.6%) patient experienced grade 3 or 4 anemia that was considered by the
investigator to be possibly study drug-related.
bConsidered to be possibly drug-related.(14.3%) patients in the pemetrexed/BSC arm and 2
(7.4%) patients in the BSC arm died during the mainten-
ance phase. In the pemetrexed/BSC arm, 3 (10.7%)
deaths were due to non-squamous NSCLC and 1 (3.6%)
death was due to an AE not related to the study drug
(sudden death). In the BSC arm, 1 (3.7%) death was
attributed to non-squamous NSCLC and 1 (3.7%) death
was due to an AE (cardiac arrest).
For the overall study period, 75/106 (70.8%) patients
who received at least 1 dose of study drug experienced
at least 1 TEAE, including 20 (71.4%) patients in the
pemetrexed/BSC arm and 18 (66.7%) patients in the
BSC arm. The occurrence of drug-related grade 3/4
TEAEs was generally low. Eight (28.6%) patients in the
pemetrexed/BSC arm, 12 (44.4%) patients in the BSC
arm, and 38/106 (35.8%) patients from the entire study
population experienced at least 1 grade 3/4 TEAE
during the overall study period. As shown in Table 4,
the most common TEAEs (≥15%) in the entire treated
patient population (n = 106) for the overall study period
were: vomiting (35.8%), fatigue (25.5%), decreased appe-
tite (24.5%), and anemia (16.0%), and the most common
grade 3/4 drug-related TEAEs in the entire treated
patient population for the entire study period were:
neutropenia (8.5%), anemia (5.7%), vomiting (1.9%), and
fatigue (1.9%).
There were a total of 17 (60.7%) deaths in the peme-
trexed/BSC arm and 15 (55.6%) deaths in the BSC arm
for the overall study period, mostly due to non-
squamous NSCLC (pemetrexed/BSC, n = 14 [50.0%];
BSC, n = 12 [44.4%]). One death in each arm was due to
Table 4 The most common treatment-emergent adverse events for the overall study period (≥10.0% )
TEAE, n (%) All Treated Patients (n = 106)a Randomized Patients (n = 55)b
Pemetrexed/BSC (n = 28) BSC (n = 27)
All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4
Vomiting 38 (35.8) 2 (1.9)c 11 (39.3) 0 (0.0) 8 (29.6) 1 (3.7)c
Fatigue 27 (25.5) 4 (3.8)d 5 (17.9) 1 (3.6)c 8 (29.6) 1 (3.7)
Decreased appetite 26 (24.5) 2 (1.9)e 8 (28.6) 0 (0.0) 5 (18.5) 0 (0.0)
Anemia 17 (16.0) 8 (7.5)f 6 (21.4) 2 (7.1)f 6 (22.2) 3 (11.1)c
Cough 15 (14.2) 1 (0.9) 3 (10.7) 0 (0.0) 4 (14.8) 0 (0.0)
Dyspnea 12 (11.3) 2 (1.9) 3 (10.7) 0 (0.0) 5 (18.5) 1 (3.7)
Nausea 15 (14.2) 0 (0.0) 6 (21.4) 0 (0.0) 4 (14.8) 0 (0.0)
Chest pain 12 (11.3) 0 (0.0) 6 (21.4) 0 (0.0) 3 (11.1) 0 (0.0)
Neutropenia 12 (11.3) 9 (8.5)c 4 (14.3) 3 (10.7)c 5 (18.5) 3 (11.1)c
Abbreviations: BSC=best supportive care; TEAE= treatment-emergent adverse event.
aThe most common TEAEs for the overall study period in the group of patients who were enrolled into the induction phase and who received at least 1 dose of
study therapy. This includes the patients who were randomized into the maintenance phase (n = 55) and the patients who were not randomized (n = 51).
bThe most common TEAEs during induction and maintenance therapy in the patients randomized to the maintenance phase arms.
cConsidered to be study drug-related.
dTwo (1.9%) patients experienced grade 3 or 4 drug-related fatigue.
eOne (0.9%) patient experienced grade 3 or 4 drug-related decreased appetite.
fSix (5.7%) patients in the all treated patient population and 1 (3.6%) randomized patient in the pemetrexed/BSC arm experienced drug-related grade 3 or
4 anemia.
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due to an AE related to study drug. Overall, 5 (17.9%)
patients in the pemetrexed/BSC arm and 3 (11.1%)
patients in the BSC arm required red blood cell transfu-
sions. During the overall study period, 1 (3.6%) patient
in the pemetrexed/BSC arm was hospitalized due to
non-squamous NSCLC and 1 (3.7%) patient in the BSC
arm was hospitalized due to an AE.
Discussion
This randomized phase 2 study met its primary endpoint
of improved PFS for the maintenance phase, based on
the Cox regression model stratified by the best overall
response to induction therapy (HR= 0.76, one-sided p-
value <0.2), indicating that continuation maintenance
therapy with pemetrexed following first-line treatment
with pemetrexed and cisplatin was sufficiently beneficial
to warrant further investigation. The median PFS times
for the maintenance phase did not differ between the
two treatment arms. Although clinical researchers may
be more familiar with median survival in comparing two
treatment groups, this single median point comparison
could be insufficient. In contrast, the HR estimate based
on Cox regression model compares the whole range of
survival times across the two groups; hence a more
effective measure of survival difference, given the pro-
portional hazard assumption is met. HR has been com-
monly used to present the primary result of survival
data in oncology trials. Disease control rates, OS and
one-year survival probabilities for the maintenance phase
were similar for both arms. The exploratory examinationsof OS for the overall study period were also similar for
both arms. In addition, both the induction therapy and
maintenance pemetrexed therapy were generally well-
tolerated and there were relatively few grade 3/4 TEAEs
observed in either study phase.
In the current study, the median PFS and OS times for
the maintenance phase for the pemetrexed/BSC arm
were 3.2 and 12.2 months, respectively, which are sub-
stantially shorter than the median PFS and OS times of
4.5 months and 15.5 months observed in the previous
phase 3 trial in patients with advanced, non-squamous
NSCLC following switch maintenance therapy with
pemetrexed [5]. It could be possible this Arab patient
population may have less access to supportive care than
patients from more affluent, industrialized countries,
and that would favor a relatively poorer prognosis,
although these statistical variations could also be
explained by the smaller size of the population of the
current study.
A primary consideration in designing a phase 2 clinical
study is to minimize the chance that a truly active agent
or regimen is erroneously rejected by keeping the prob-
ability of type II error (false-negative) low [11]. We
attempted to do this by using a higher type I error rate
(alpha = 0.2) than would typically be used in a larger
phase 3 trial (alpha = 0.05). In addition, stratified PFS
was prospectively determined as the primary endpoint of
the trial to minimize potential confounding from differ-
ences in response to induction therapy. This choice
appears to be justified given that a higher proportion of
patients in the BSC arm responded to the induction
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25.0%). Therefore, it is possible that more patients in the
BSC arm may have had a better general prognosis.
Study design limitations include the small sample size
and the randomization error, which resulted in patients
being randomized to the pemetrexed/BSC and BSC
arms in a 1:1 ratio rather than a 2:1 ratio. Consequently,
fewer patients than originally planned were randomized
to the pemetrexed/BSC arm, although this did not
preclude evaluation of the primary study hypothesis.
These limitations may partly account for the lack of sig-
nificant between-arm differences observed for the effi-
cacy outcomes. Another potential limitation that could
be worth mentioning is the absence of a placebo arm.
The investigator-assessed response and disease progres-
sion are normally not precisely measured as OS is (with
an exact date of death), and therefore may be subject to
assessment bias, particularly in open-label studies such
as this one. Obviously, we cannot rule out this possibil-
ity. However, as this is a phase 2 proof of concept study
rather than a confirmatory phase 3 trial, an independent
review panel was not used to validate the investigator
assessments. The administration of placebos in oncology
studies was reviewed by Chvetzoff and Tannock [12], it
was shown to improve symptom control (such as pain
and appetite) but did not lead to tumor response. Hence,
given that our primary and secondary endpoints were
PFS, OS and tumor response rate, we argue that the
absence of a placebo would not introduce significant
bias to our efficacy outcome measures in this trial.
Recent results of a phase 3 trial provide stronger evi-
dence of the potential benefit of continuation peme-
trexed maintenance therapy [13]. The PARAMOUNT
study investigated whether pemetrexed continuation main-
tenance therapy would improve PFS after pemetrexed-
cisplatin induction therapy in patients with advanced,
non-squamous NSCLC [13]. Randomized patients must
not have progressed during the induction therapy and
must have had an ECOG PS of 0 or 1 at the end of
induction therapy. A total of 539 (57.4%) patients
were randomized in a 2:1 ratio to continuation mainten-
ance with pemetrexed/BSC (n= 359) or placebo (normal
saline)/BSC (n= 180). Randomization was stratified for
baseline disease stage, the best overall response to the
induction therapy, and the ECOG PS just prior to
randomization [13]. The study had 90% power to show a
statistically significant between-arm difference in PFS for
the maintenance phase at an alpha of 0.05, assuming
that the true unadjusted HR was 0.65. A median of
4 cycles of maintenance therapy was delivered in each
arm. PFS from randomization was significantly longer
for the pemetrexed/BSC arm than the placebo/BSC arm
(median PFS: 4.1 vs 2.8 months, respectively; unadjusted
HR=0.62, 95% CI: 0.49 to 0.79; p = 0.00006) [13].Similarly, the exploratory analysis of the overall PFS
(from induction) showed it was significantly longer for
the pemetrexed/BSC arm than the placebo/BSC arm
(median PFS: 6.9 vs 5.6 months; HR= 0.59, 95% CI: 0.47
to 0.74, p < 0.00001). The independently reviewed disease
control rate for the maintenance phase was 71.8% for the
pemetrexed/BCS arm and 59.6% for the placebo/BSC
arm (p = 0.009). Patients achieved a median OS of
13.9 months from randomization (16.9 months from
start of induction) on the pemetrexed continuation
maintenance arm compared to 11.0 months from
randomization (14.0 months from start of induction) on
the placebo arm [14]. The main differences in adverse
events reported in the PARAMOUNT trial between the
two arms were higher grade 3/4 toxicity rates for peme-
trexed as follows: fatigue (4.2% vs 0.6%, respectively),
anemia (4.5% vs 0.6%), and neutropenia (3.6% vs 0%)
[14]. Consistent with the safety results for our study, the
safety data from the PARAMOUNT study showed that
pemetrexed maintenance therapy was generally well-
tolerated [5,14]. The finding of an optimal maintenance
therapy for patients with locally advanced or metastatic
non-squamous NSCLC, who achieved disease control
after first-line chemotherapy, is still the subject of study.Conclusions
The results of our study showed that continuous peme-
trexed maintenance therapy following 4 cycles of
pemetrexed-cisplatin induction therapy resulted in pro-
mising PFS with an acceptable safety profile in a Middle
Eastern population with advanced non-squamous NSCLC,
and that it is worthy of further investigation. Data currently
published for the benefit of maintenance therapy with
pemetrexed also support the results of our study.
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